12-Month Double-blind, Randomized, Multicenter, Active-controlled, Parallel-group Study Comparing the Efficacy and Safety of 100ug NeuroVax Once Monthly Intramuscular Injection Versus Interferon ß-1a Administered im Once Weekly in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase

Trial Profile

12-Month Double-blind, Randomized, Multicenter, Active-controlled, Parallel-group Study Comparing the Efficacy and Safety of 100ug NeuroVax Once Monthly Intramuscular Injection Versus Interferon ß-1a Administered im Once Weekly in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Dec 2013

At a glance

  • Drugs IR 902 (Primary) ; Interferon beta-1a
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Sponsors Immune Response BioPharma
  • Most Recent Events

    • 05 Dec 2013 New trial record
    • 24 Nov 2013 This trial is expected to begin enrolling patients in quarter 2, 2015, according to an Immune Response BioPharma media release. The company is discussing funding of NeuroVax development with US government funding agencies.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top